----

|   | ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|--------|---------|--------------------------------------------------------------------------------------|
|   | ☐ | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT |
|--------|---------|-----------------------------------------------------------------|
| Delaware                        |   | 59-3733133              |
|---------------------------------|--------|-------------------------|
| (State or other Jurisdiction of |   | (IRS Employer I.D. No.) |
| Incorporation or Organization)  |   |                    |
| Title of each class |   | Name of each exchange on which registered |
|---------------------|--------|-------------------------------------------|
| None                |   | None                                      |
| Common Stock $.0001 Par Value |
|-------------------------------|
| Title of Class                |

----

| Large accelerated filer  ☐ | Accelerated filer ☐                |
|--------------------------------------------|-----------------------------------------------|
| Non-accelerated filer  ☐   | Smaller reporting company   ☑ |

----

| PART I   |                                                                                                         | 1  |
|----------|--------------------------------------------------------------------------------------------------------------|----|
| ITEM 1.  | DESCRIPTION OFBUSINESS                                                                                       | 1  |
| ITEM 1A. | RISK FACTORS                                                                                                 | 12 |
| ITEM 1B. | UNRESOLVED STAFF COMMENTS                                                                                    | 23 |
| ITEM 2.  | PROPERTIES                                                                                                   | 23 |
| ITEM 3.  | LEGAL PROCEEDINGS                                                                                            | 23 |
| ITEM 4.  | MINE SAFETY DISCLOSURES                                                                                      | 24 |
| PART II  | 25                                                                                                           |
| ITEM 5.  | MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES | 25 |
| ITEM 6.  | SELECTED FINANCIAL DATA                                                                                      | 26 |
| ITEM 7.  | MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION                         | 26 |
| ITEM 7A. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK                                                   | 31 |
| ITEM 8.  | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA                                                                  | 32 |
| ITEM 9.  | CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE                         | 51 |
| ITEM 9A. | CONTROLS AND PROCEDURES                                                                                      | 52 |
| ITEM 9B. | OTHER INFORMATION                                                                                            | 54 |
| PART III | 54                                                                                                           |
| ITEM 10. | DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE                                                       | 54 |
| ITEM 11. | EXECUTIVE COMPENSATION                                                                                       | 57 |
| ITEM 12. | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS               | 60 |
| ITEM 13. | CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE                                     | 62 |
| ITEM 14. | PRINCIPAL ACCOUNTING FEES AND SERVICES                                                                       | 62 |
| PART IV  | 62                                                                                                           |
| ITEM 15. | EXHIBITS                                                                                                     | 62 |

----

----

----

----

----

----

----

|  | · | the Company will be able to comply with the covenants under the Pacific Leaf Note Purchase Agreement so as to enable the Company to receive all of the anticipated funding thereunder; |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | there will not be cost over-runs in connection with the purchase and/or lease of the cultivation facility and related equipment resulting in the proceeds of the Loan being insufficient to enable GBSN to complete the installation and commence production of cannabis for medical purposes; |
|--|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | a state business license to operate the medical cannabis facility will be issued, or that the Company or GBSN will not violate existing or newly imposed state, county and city regulations in Nevada that would significant restrict or prohibit its proposed business activities; or |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | the proposed business to be conducted by GBSN with the proceeds of the Loan will prove profitable to the Company or its subsidiaries. |
|--|--------|---------------------------------------------------------------------------------------------------------------------------------------|

----

----

|  | · | In January, the Company vacated its offices at 6450 Cameron in Las Vegas, saving $7,000 per month in rent. In May 2016, The Company moved its corporate offices to the Teco facility upon receiving a Certificate of Occupancy for the facility. |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | In March 2016 the Company implemented a furlough of all science-related officers and employees. These employees are expected to return to work the earlier of a) the receipt of revenues from sales of cannabis grown at the Teco facility; or b) identification of critical time-sensitive tasks or projects combined with sufficient resources to pay for the performance of these tasks or projects. As a result of these measures, and other layoffs the Company reduced its expenditures by approximately $45,000 per month. |
|--|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

----

----

|  | · | we will be able to comply with our loan covenants to enable it to receive all of the anticipated funding thereunder; |
|--|--------|----------------------------------------------------------------------------------------------------------------------|

|  | · | there will not be cost over-runs in connection with the purchase and/or lease of the cultivation facility and related equipment resulting in the proceeds of the loan being insufficient to enable us to timely complete the facility and commence production of cannabis for medical purpose; |
|--|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | a final certificate to cultivate medical cannabis at the Las Vegas facility will be issued, or we or GBSN will not violate existing or newly imposed state, county and city regulations in Nevada that would significant restrict or prohibit proposed business activities; or |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | the proposed business to be conducted by GBSN will prove profitable.  |
|--|--------|----------------------------------------------------------------------------|

----

----

|   |
|--------|

----

----

----

|  | · | The need for continued development of our financial and information management systems; |
|--|--------|-----------------------------------------------------------------------------------------|

|  | · | The need to manage strategic relationships and agreements with manufacturers, customers and partners; and |
|--|--------|-----------------------------------------------------------------------------------------------------------|

|  | · | Difficulties in hiring and retaining skilled management, technical, and other personnel necessary to support and manage our business.  |
|--|--------|---------------------------------------------------------------------------------------------------------------------------------------------|

----

----

|  | · | Lack of a functioning audit committee consisting of independent Board members as well as a lack of expertise with respect to the application of US GAAP and SEC rules and regulations and; |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Inadequate segregation of duties consistent with control objectives; and  |
|--|--------|--------------------------------------------------------------------------------|

|  | · | Lack of audit committee members with prior experience in financial accounting and the application of US GAAP. |
|--|--------|---------------------------------------------------------------------------------------------------------------|

----

----

----

----

| Fiscal Year 2016 |   | High ($) |   |   | Low ($) |   |
|------------------|--------|----------|--------|--------|---------|--------|
| Fourth Quarter   |   | $        | 0.24   |   |    | $      | 0.14 |   |
| Third Quarter    |   | $        | 0.39   |   |    | $      | 0.11 |   |
| Second Quarter   |   | $        | 0.41   |   |    | $      | 0.01 |   |
| First Quarter    |   | $        | 0.74   |   |    | $      | 0.19 |   |
| Fiscal Year 2015 |   |     |   |   |    |   |   |   |
| Fourth Quarter   |   | $        | 0.48   |   |    | $      | 0.15 |   |
| Third Quarter    |   | $        | 1.51   |   |    | $      | 0.31 |   |
| Second Quarter   |   | $        | 1.48   |   |    | $      | 0.67 |   |
| First Quarter    |   | $        | 6.28   |   |    | $      | 0.98 |   |

----

----

|                                          |   | Twelve months ended March 31, |       |
|-----------------------------------------------|--------|-------------------------------|------------|
|                                          |   | 2016                          |       |   | 2015 |   |
|                                          |   |                          |       |   |   |   |
| Revenue                                       |   | $                             | -          |   |   | $ | - |   |
| General and administrative expenses           |   |                          | 6,958,769  |   |   |   | 7,973,850 |   |
| Other income/(expense)                        |   |                          | (120,209   | ) |   |   | 135 |   |
| Loss attributable to non-controlling interest |   |                          | (307,643   | ) |   |   | (250,960 | ) |
| Net income/(loss)                             |   |                          | (6,771,335 | ) |   |   | (7,722,755 | ) |

----

----

----

----

----

|                                                                                            | Page     |
|-------------------------------------------------------------------------------------------------|----------|
| REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMS                                        | 33       |
| FINANCIAL STATEMENTS:                                                                           |     |
| CONSOLIDATED BALANCE SHEETS AS OF  MARCH 31, 2016 AND MARCH 31, 2015                       | 35       |
| CONSOLIDATED STATEMENTS OF OPERATIONS - YEARS ENDED MARCH 31, 2016 AND 2015                     | 36  |
| CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY/(DEFICIT) - YEARS ENDED MARCH 31, 2016 AND 2015 | 37       |
| CONSOLIDATED STATEMENTS OF CASH FLOWS - YEARS ENDED MARCH 31, 2016 AND 2015                     | 38       |
| NOTES TO FINANCIAL STATEMENTS                                                                   | 39       |

----

----

----

| GROWBLOX SCIENCES, INC. AND SUBSIDIARIES                                                                                                                        |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| CONSOLIDATED BALANCE SHEETS                                                                                                                      |   |
|                                                                                                                                                            |   |   |   |   |   |   |
|                                                                                                                                                            |   |   |   |   |   |   |
|                                                                                                                                                            |   | March 31, 2016 |   |   | March 31, 2015 |   |
| CURRENT ASSETS:                                                                                                                                                 |   |   |   |   |   |   |
|    Cash and cash equivalents                                                                                                                     |   | $ | 34,824 |   |   | $ | - |   |
|    Accounts receivable                                                                                                                           |   |   | 67,862 |   |   |   | 50,000 |   |
|    Prepaid expenses                                                                                                                              |   |   | 104,851 |   |   |   | 190,374 |   |
|     TOTAL CURRENT ASSETS                                                                                                                         |   |   | 207,537 |   |   |   | 240,374 |   |
| Property and Equipment, Net                                                                                                                                     |   |   | 1,953,048 |   |   |   | 913,642 |   |
| Intangible Assets, Net                                                                                                                                          |   |   | 3,555 |   |   |   | 3,555 |   |
| Deposits and Prepayments                                                                                                                                        |   |   | 271,455 |   |   |   | 293,920 |   |
|     TOTAL ASSETS                                                                                                                                 |   | $ | 2,435,595 |   |   | $ | 1,451,491 |   |
| CURRENT LIABILITIES:                                                                                                                                            |   |   |   |   |   |   |   |   |
|    Accounts Payable                                                                                                                                   |   | $ | 902,123 |   |   | $ | 677,230 |   |
|    Accrued Interest                                                                                                                                   |   |   | 61,786 |   |   |   | 230 |   |
|    Accrued Liabilities                                                                                                                                |   |   | 834,348 |   |   |   | 70,777 |   |
|    Notes Payable, net of unamortized discount of $0.4 million and $0 at March 31, 2016 and 2015, respectively                                         |   |   | 463,532 |   |   |   | 182,000 |   |
|    Deferred Revenue                                                                                                                                   |   |   | - |   |   |   | 54,408 |   |
|    Deferred Compensation                                                                                                                              |   |   | - |   |   |   | 1,522,537 |   |
|     TOTAL CURRENT LIABILITIES                                                                                                               |   |   | 2,261,789 |   |   |   | 2,507,182 |   |
|    Note Payable                                                                                                                                       |   |   | 2,148,556 |   |   |   | - |   |
|    Deferred Revenue                                                                                                                                   |   |   | - |   |   |   | 220,506 |   |
|    Other Liabilities                                                                                                                                  |   |   | - |   |   |   | 654,968 |   |
|     TOTAL LIABILITIES                                                                                                                            |   |   | 4,410,345 |   |   |   | 3,382,656 |   |
| Commitments and Contingencies (Note 11)                                                                                                                         |   |   |   |   |   |
| STOCKHOLDERS' (DEFICIT)/ EQUITY:                                                                                                                                |   |   |   |   |   |   |   |   |
|    Common Stock, $0.0001 par value, 250,000,000 shares authorized, 47,335,147 and 35,972,929 shares issued and outstanding at March 31, 2016 and 2015 |   |   | 4,733 |   |   |   | 3,597 |   |
|    Deferred Stock Compensation                                                                                                                        |   |   | 2,240,662 |   |   |   | 1,573,032 |   |
|    Additional Paid In Capital                                                                                                                         |   |   | 16,638,318 |   |   |   | 10,751,691 |   |
|    Accumulated Deficit                                                                                                                                |   |   | (20,779,860 | ) |   |   | (14,008,525 | ) |
|     TOTAL GROWBLOX SCIENCES, INC. STOCKHOLDERS' (DEFICIT)/EQUITY                                                                                 |   |   | (1,896,147 | ) |   |   | (1,680,205 | ) |
|    Non-controlling interest                                                                                                                           |   |   | (78,603 | ) |   |   | (250,960 | ) |
|     TOTAL (DEFICIT)/EQUITY                                                                                                                       |   |   | (1,974,750 | ) |   |   | (1,931,165 | ) |
|     TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT)/EQUITY                                                                                         |   | $ | 2,435,595 |   |   | $ | 1,451,491 |   |
|                                                                                                                                                            |   |   |   |   |   |   |   |   |
| The accompanying notes are an integral part of these consolidated financial statements                                                                          |   |

----

| GROWBLOX SCIENCES, INC. AND SUBSIDIARIES                                               |   |
|----------------------------------------------------------------------------------------|--------|
| STATEMENTS OF OPERATIONS                                      |   |
|                                                                                   |   |   |   |   |   |   |
|                                                                                   |   |   |   |   |   |   |
|                                                                                   |   | For the Twelve Months Ended March 31, |   |
|                                                                                   |   | 2016 |   |   | 2015 |   |
|                                                                                   |   |   |   |   |   |   |
| NET REVENUE                                                                            |   | $ | - |   |   | $ | - |   |
| GENERAL AND ADMINISTRATIVE EXPENSES                                                    |   |   | 6,958,769 |   |   |   | 7,973,850 |   |
| LOSS FROM OPERATIONS                                                                   |   |   | (6,958,769 | ) |   |   | (7,973,850 | ) |
| OTHER (EXPENSE) INCOME                                                                 |   |   |   |   |   |   |   |   |
|    Interest Expense                                                     |   |   | (105,204 | ) |   |   | - |   |
|    Other (Expense) Income                                                    |   |   | (15,005 | ) |   |   | 135 |   |
|     Total other expense                                                 |   |   | (120,208 | ) |   |   | 135 |   |
| NET LOSS                                                                               |   |   | (7,078,978 | ) |   |   | (7,973,715 | ) |
|    Net loss attributable to non-controlling interest                         |   |   | (307,643 | ) |   |   | (250,960 | ) |
| NET LOSS ATTRIBUTABLE TO GROWBLOX SCIENCES, INC.                                       |   | $ | (6,771,335 | ) |   | $ | (7,722,755 | ) |
|    Net loss per share - basic and diluted                               |   | $ | (0.15 | ) |   | $ | (0.26 | ) |
|    Weighted average common shares outstanding - basic and diluted            |   |   | 44,911,521 |   |   |   | 29,520,288 |   |
|                                                                                   |   |   |   |   |   |   |   |   |
| The accompanying notes are an integral part of these consolidated financial statements |   |

----

| GROWBLOX SCIENCES, INC. AND SUBSIDIARIES                                                                       |   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| STATEMENTS OF STOCKHOLDERS' DEFICIENCY                                                                         |   |
|                                                                                                                                                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                                                                                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                                                                                                                                                                   |   | Shares |   |   | Amount |   |   | Additional Paid-In Capital |   |   | Accumulated Deficit |   |   | Non-Controlling Interest |   |   | Total |   |
|                                                                                                                                                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at March 31, 2014                                                                                                                                                                                                              |   |   | 7,268,948 |   |   |   | 727 |   |   |   | 5,198,659 |   |   |   | (6,212,755 | ) |   |   | - |   |   |   | (1,013,369 | ) |
|                                                                                                                                                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | - |   |
| Sale of stock subscription                                                                                                                                                                                                             |   |   | 14,457,000 |   |   |   | 1,446 |   |   |   | 4,226,762 |   |   |   | - |   |   |   | - |   |   |   | 4,228,208 |   |
| Issuance of stock for debt conversion                                                                                                                                                                                                  |   |   | 4,470,747 |   |   |   | 447 |   |   |   | 1,514,169 |   |   |   | - |   |   |   | - |   |   |   | 1,514,616 |   |
| Exercise of warrants for stock                                                                                                                                                                                                         |   |   | 1,032,190 |   |   |   | 103 |   |   |   | 206,335 |   |   |   | - |   |   |   | - |   |   |   | 206,438 |   |
| Investment in subsidiary                                                                                                                                                                                                               |   |   | - |   |   |   | - |   |   |   | 127,500 |   |   |   | - |   |   |   | - |   |   |   | 127,500 |   |
| Stock issuance costs                                                                                                                                                                                                                   |   |   | - |   |   |   | - |   |   |   | (594,750 |   |   |   | - |   |   |   | - |   |   |   | (594,750 | ) |
| Induced dividend from warrant exercises                                                                                                                                                                                                |   |   | - |   |   |   | - |   |   |   | 73,015 |   |   |   | (73,015 | ) |   |   | - |   |   |   | - |   |
| Stock compensation                                                                                                                                                                                                                     |   |   | 8,744,044 |   |   |   | 874 |   |   |   | 1,573,033 |   |   |   | - |   |   |   | - |   |   |   | 1,573,907 |   |
| Net loss                                                                                                                                                                                                                               |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (7,722,755 | ) |   |   | - |   |   |   | (7,722,755 | ) |
| Loss attributable in non-controlling interest                                                                                                                                                                                          |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (250,960 | ) |   |   | (250,960 | ) |
|                                                                                                                                                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at March 31, 2015                                                                                                                                                                                                              |   |   | 35,972,929 |   |   |   | 3,597 |   |   |   | 12,324,723 |   |   |   | (14,008,525 | ) |   |   | (250,960 | ) |   |   | (1,931,165 | ) |
|                                                                                                                                                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of stock for debt conversion                                                                                                                                                                                                  |   |   | 2,219,750 |   |   |   | 222 |   |   |   | 939,132 |   |   |   | - |   |   |   | - |   |   |   | 939,354 |   |
| Exercise of warrants for stock                                                                                                                                                                                                         |   |   | 9,119,135 |   |   |   | 912 |   |   |   | 1,505,495 |   |   |   | - |   |   |   | - |   |   |   | 1,506,407 |   |
| Issuance of restricted stock                                                                                                                                                                                                           |   |   | 1,882,400 |   |   |   | 188 |   |   |   | 206,310 |   |   |   | - |   |   |   | - |   |   |   | 206,499 |   |
| Exercises of stock options                                                                                                                                                                                                             |   |   | 100,000 |   |   |   | 10 |   |   |   | 16,990 |   |   |   | - |   |   |   | - |   |   |   | 17,000 |   |
| Share based compensation expense                                                                                                                                                                                                       |   |   | - |   |   |   | - |   |   |   | 3,645,079 |   |   |   | - |   |   |   | - |   |   |   | 3,645,079 |   |
| Cancelation of restricted stock                                                                                                                                                                                                        |   |   | (2,292,400 |   |   |   | (229 |   |   |   | (257,165 |   |   |   | - |   |   |   | - |   |   |   | (257,394 | ) |
| Issuance of stock for cash                                                                                                                                                                                                             |   |   | 333,333 |   |   |   | 33 |   |   |   | 99,967 |   |   |   | - |   |   |   | - |   |   |   | 100,000 |   |
| Beneficial conversion feature on notes payable                                                                                                                                                                                         |   |   |   |   |   |   |   |   |   |   | 398,449 |   |   |   | - |   |   |   | - |   |   |   | 398,449 |   |
| Contributions from non-controlling interest                                                                                                                                                                                            |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 480,000 |   |   |   | 480,000 |   |
| Net Loss                                                                                                                                                                                                                               |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (6,771,335 | ) |   |   |   |   |   |   | (6,771,335 | ) |
| Loss attributable to non-controlling interest                                                                                                                                                                                          |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (307,643 | ) |   |   | (307,643 | ) |
|                                                                                                                                                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at March 31, 2016                                                                                                                                                                                                              |   |   | 47,335,147 |   |   |   | 4,733 |   |   |   | 18,878,980 |   |   |   | (20,779,860 | ) |   |   | (78,603 | ) |   |   | (1,974,750 | ) |
|                                                                                                                                                                                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| The accompanying notes are an integral part of these consolidated financial statements                         |   |

----

| GROWBLOX SCIENCES, INC. AND SUBSIDIARIES                                              |   |
|----------------------------------------------------------------------------------------------------------------|--------|
| CONSOLIDATED STATEMENTS OF CASH FLOWS                                                 |   |
|                                                                                                           |   |   |   |   |   |   |
|                                                                                                           |   |   |   |   |   |   |
|                                                                                                           |   | Twelve Months Ended March 31, |   |
|                                                                                                           |   | 2016 |   |   | 2015 |   |
| OPERATING ACTIVITIES:                                                                                          |   |   |   |   |   |   |
| Net loss                                                                                                       |   | $ | (7,078,978 |   |   | $ | (7,973,715 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities:                                    |   |   |   |   |   |
|    Depreciation and amortization                                                                     |   |   | 177,122 |   |   |   | 69,120 |   |
|    Stock-based compensation                                                                          |   |   | 1,828,616 |   |   |   | 3,768,120 |   |
|    Amortization of debt discount                                                                     |   |   | 43,122 |   |   |   | - |   |
| Changes in operating assets and liabilities:                                                                   |   |   |   |   |   |   |   |   |
|    Accounts receivable                                                                               |   |   | (17,862 |   |   |   | (50,000 | ) |
|    Stock subscription receivable                                                                     |   |   | - |   |   |   | 150,000 |   |
|    Prepaid expenses                                                                                  |   |   | 85,523 |   |   |   | (190,374 | ) |
|    Change in other assets                                                                            |   |   | - |   |   |   | - |   |
|    Accounts payable                                                                                  |   |   | 641,379 |   |   |   | 657,468 |   |
|    Stock subscription payable                                                                        |   |   | - |   |   |   | (10,000 | ) |
|    Accrued expenses                                                                                  |   |   | 757,071 |   |   |   | 76,758 |   |
|     Net cash used in operating activities                                                       |   |   | (3,564,008 |   |   |   | (3,502,623 | ) |
| INVESTING ACTIVITIES:                                                                                          |   |   |   |   |   |   |   |   |
|    Purchase of property and equipment                                                                |   |   | (881,595 |   |   |   | (937,660 | ) |
|    Change in deposits                                                                                |   |   | 22,465 |   |   |   | (293,920 | ) |
|    Other investing activities                                                                        |   |   | - |   |   |   | 274,915 |   |
|     Net cash used in investing activities                                                       |   |   | (859,130 |   |   |   | (956,665 | ) |
| FINANCING ACTIVITIES:                                                                                          |   |   |   |   |   |   |   |   |
|    Proceeds from issuance of common stock and warrants                                               |   |   | 1,479,688 |   |   |   | 4,070,706 |   |
|    Proceeds from non-controlling interest                                                            |   |   | 480,000 |   |   |   | 150,000 |   |
|    Proceeds from notes payable                                                                       |   |   | 2,204,872 |   |   |   | 30,000 |   |
|    Cash used to purchase warrants                                                                    |   |   | (56,000 |   |   |   | - |   |
|    Other financing activities                                                                        |   |   | 349,402 |   |   |   | (3,245 | ) |
|    Investment in subsidiary                                                                          |   |   | - |   |   |   | (127,500 | ) |
|     Net cash provided by financing activities                                              |   |   | 4,457,962 |   |   |   | 4,119,961 |   |
| Net change in cash and cash equivalent                                                                         |   |   | 34,824 |   |   |   | (339,327 | ) |
| CASH AND CASH EQUIVALENT AT BEGINNING OF PERIOD                                                                |   |   | - |   |   |   | 339,327 |   |
| CASH AND CASH EQUIVALENT AT END OF PERIOD                                                                      |   | $ | 34,824 |   |   | $ | - |   |
| Non-cash transactions:                                                                                         |   |   |   |   |   |   |   |   |
|    Stock issued to settle convertible debt                                                           |   | $ | 377,735 |   |   | $ | 1,262,411 |   |
|    Market Price over warrant exercise and transfer price                                             |   | $ | - |   |   | $ | 73,015 |   |
|    Discount on beneficial conversion feature on convertible notes payable                            |   | $ | 398,449 |   |   | $ | - |   |
|                                                                                                           |   |   |   |   |   |   |   |   |
| The accompanying notes are an integral part of these consolidated financial statements     |   |

----

----

| - | Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.                                                                                                                                              |
|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - | Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. |
| - | Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement.                                                                                                                                                                              |

----

----

----

|                                           |   | March 31,    |      |
|------------------------------------------------|--------|-----------------------------|-----------|
|                                           |   | 2016                        |      |   | 2015 |   |
| Computer and software                          |   | $                           | 151,748   |   |   | $ | 136,302 |   |
| Machinery and equipment                        |   |                        | 641,898   |   |   |   | 620,479 |   |
| Leaseholds                                     |   |                        | 363,318   |   |   |   | 226,697 |   |
| Construction in progress                       |   |                        | 1,043,042 |   |   |   | - |   |
|                                           |   |                        | 2,200,006 |   |   |   | 983,478 |   |
| Less accumulated depreciation and amortization |   |                        | (246,958  | ) |   |   | (69,836 | ) |
| Property and equipment, net                    |   | $                           | 1,953,048 |   |   | $ | 913,642 |   |

----

|                                           |   | 2016   |       |   | 2015   |   |
|------------------------------------------------|--------|--------|------------|--------|--------|--------|
| Tax benefit computed at U.S. statutory rates   |   | $      | (2,263,566 | )      |   | $      | (2,669,517 | ) |
| Increases (decreases) in taxes resulting from: |   |   |       |   |   |   |   |   |
| Non-deductible items                           |   |   | (113,788   | )      |   |   | (3,058 | ) |
| Change in valuation allowance                  |   |   | 2,388,354  |   |   |   | 2,682,575 |   |
| State taxes                                    |   |   | (11,000    | )      |   |   | (10,000 | ) |
| Total                                          |   | $      | -          |   |   | $      | - |   |
|                            |   | 2016   |       |   | 2015   |   |
|---------------------------------|--------|--------|------------|--------|--------|--------|
| Deferred tax assets:            |   |   |       |   |   |   |
| Net operating loss carryforward |   | $      | 4,416,060  |   |   | $      | 3,080,750 |   |
| Depreciation expense            |   |   | (11,713    | )      |   |   | (125,507 | ) |
| Stock based compensation        |   |   | 761,825    |   |   |   | 1,391,032 |   |
| Total deferred tax assets       |   |   | 5,166,172  |   |   |   | 4,346,275 |   |
| Less valuation allowance        |   |   | (5,166,172 | )      |   |   | (4,346,275 | ) |
| Net deferred tax asset          |   | $      | -          |   |   | $      | - |   |

----

|  | · | The Company issued 2,219,750 shares of restricted common stock in connection with the conversion of $0.9 million in indebtedness owed by us to various persons at a conversion price of approximately $0.30 per share. |
|--|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | The Company issued 1,168,000 shares of restricted common stock as compensation for consulting services.  The Company recorded approximately $0.1 million in related compensation expense.  The closing price of the Company's stock on the date of grant is used as the fair value for the issuances of restricted stock. |
|--|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

|                          |   | Warrants Outstanding |       |
|-------------------------------|--------|----------------------|------------|
|                          |   | Number of Shares     |       |   | Exercise Price |   |
|                          |   |                 |       |   |   |   |
| Outstanding at April 1, 2014  |   |                 | 3,000,000  |   |   | $ | 1.00-$2.00 |   |
| Warrants issued               |   |                 | 19,998,446 |   |   | $ | 1.00-$2.00 |   |
| Warrants exercised            |   |                 | (1,032,190 | ) |   | $ | 0.20-$0.21 |   |
| Outstanding at March 31, 2015 |   |                 | 21,966,256 |   |   |   |   |   |
| Warrants issued               |   |                 | 5,665,000  |   |   | $ | 0.45-$0.50 |   |
| Warrants exercised            |   |                 | (7,977,945 | ) |   | $ | 0.20-$0.21 |   |
| Warrants expired/cancelled    |   |                 | (337,977   | ) |   | $ | 1.00-$2.00 |   |
| Outstanding at March 31, 2016 |   |                 | 19,315,334 |   |   |   |   |   |

----

|             |   | Unrecognized Compensation Cost ($) |      |   | Weighted Averge Period (years) |   |
|------------------|--------|------------------------------------|-----------|--------|--------------------------------|--------|
| Restricted Stock |   |                               | 158,000   |   |                           |   | 8.53 |   |
| Stock Options    |   |                               | 900,735   |   |                           |   | 9.23 |   |
| Total            |   |                               | 1,058,735 |   |                           |   | 9.26 |   |

|                        |   | Twelve months ended |   |
|-----------------------------|--------|---------------------|--------|
|                        |   | March 31, 2016      |   |   | March 31, 2015 |   |
| Weighted-average volatility |   |                | 190.44 | % |   |   | 171.08 | % |
| Expected term (in years)    |   |                | 10     |   |   |   | 10 |   |
| Risk-free interest rate     |   |                | 1.57   | % |   |   | 1.47 | % |

|                                                |   | Options |      |   | Weighted Average Exercise Price ($) |   |   | Weighted Average Remaining Contractual Life (years) |   |   | Aggregate Intrinsic Value ($) |   |
|-----------------------------------------------------|--------|---------|-----------|--------|-------------------------------------|--------|--------|-----------------------------------------------------|--------|--------|-------------------------------|--------|
| Outstanding at April 1, 2014                        |   |    | -         |   |                                |   |   |                                                |   |   |                          |   |   |
| Granted                                             |   |    | 1,962,000 |   |                                |   | 0.17   |                                                |   |   |                          |   |   |   |
| Exercised                                           |   |    | -         |   |                                |   |   |                                                |   |   |                          |   |   |   |
| Outstanding at March 31, 2015                       |   |    | 1,962,000 |   |                                |   | 0.17   |                                                |   |   | 9.99                          |   |   |   | 10,962 |   |
| Granted                                             |   |    | 1,400,000 |   |                                |   | 0.24   |                                                |   |   |                          |   |   |   |   |   |
| Exercised                                           |   |    | (100,000  | )      |                                |   | 0.17   |                                                |   |   |                          |   |   |   |   |   |
| Forfeited                                           |   |    | (762,000  | )      |                                |   | 0.17   |                                                |   |   |                          |   |   |   |   |   |
| Outstanding at March 31, 2016                       |   |    | 2,500,000 |   |                                |   | 0.25   |                                                |   |   | 9.23                          |   |   |   | 15,075 |   |
| Fully vested and expected to vest at March 31, 2016 |   |    | 2,120,000 |   |                                |   | 0.25   |                                                |   |   |                          |   |   |   | 9,045 |   |
| Exercisable at March 31, 2016                       |   |    | 380,000   |   |                                |   | 0.17   |                                                |   |   |                          |   |   |   | 6,030 |   |

----

|                         |   | Shares |     |   | Weighted Average Grant Date Fair Value ($) |   |
|------------------------------|--------|--------|----------|--------|--------------------------------------------|--------|
| Balance at April 1, 2014     |   |   | -        |   |                                       |   |   |
| Granted                      |   |   | 980,000  |   |                                       |   |   |
| Vested                       |   |   | (417,500 | )      |                                       |   |   |
| Non-vested at March 31, 2015 |   |   | 562,500  |   |                                       |   | 1.20 |   |
| Granted                      |   |   | 270,000  |   |                                       |   |   |   |
| Vested                       |   |   | (441,667 | )      |                                       |   |   |   |
| Forfeited/Cancelled          |   |   | (204,167 | )      |                                       |   |   |   |
| Non-vested at March 31, 2016 |   |   | 186,667  |   |                                       |   | 0.35 |   |

----

----

----

----

|  | · | ineffective controls over period end financial disclosure and reporting processes including not having a functioning audit committee consisting of independent Board members as well as lack of expertise with respect to the application of US GAAP and SEC rules and regulations. |
|--|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | one individual who, as an officer and director of the Company, has sole access and authority to receive cash and make cash disbursements |
|--|--------|------------------------------------------------------------------------------------------------------------------------------------------|

----

| Name                    |   | Age |   | Position                                                                                |
|-------------------------|--------|-----|--------|-----------------------------------------------------------------------------------------|
| John Poss               |   | 68  |   | Chief Executive Officer, Chief Financial Officer, Chief Operating Officer, and Director |
| Craig Ellins            |   | 63  |   | Chief Innovation Officer and Chairman of the Board                                      |
| Dr. Andrea Small-Howard |   | 47  |   | Chief Science Officer and Director                                                      |
| Leslie Bocskor          |   | 51  |   | Director                                                                                |
| Shane Terry             |   | 37  |   | Director                                                                                |

----

----

|   | 1) | the subject of any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;                                                                              |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | 2) | convicted in a criminal proceeding or is subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);                                                                                                                                                        |
|   | 3) | subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities; or |
|   | 4) | found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law.                                                                                                     |

----

----

| Name and Position                                           | Year   |   | Salary  |    |   | Stock Awards (1) |    |   | Option Awards (2) |   |   | Total  |   |
|-------------------------------------------------------------|--------|--------|---------|---------|--------|------------------|---------|--------|-------------------|--------|--------|--------|--------|
| John Poss, CEO, CFO, COO, and Director                      | 2016   |   | $       | 55,055  |   |             | $       | -      |              |   |   |   |   | $ | 179,585 |   |   | $ | 234,640 |   |
|  2015                                                  |   | $      | -       |    |   | $                | -       |   |              |   |   |   | $      | - |   |   | $ | - |   |
|                                                        |   |   |    |    |   |             |    |   |              |   |   |   |   |   |   |   |   |   |   |   |
| Craig Ellins, CIO and Chairman of the Board                 | 2016   |   | $       | 137,192 |   |             | $       | -      |              |   |   |   |   | $ | 860,000 |   |   | $ | 997,192 |   |
|  2015                                                  |   | $      | 168,617 |    |   | $                | -       |   |              |   | (3     | )      |   | $ | - |   |   | $ | 168,617 |   |
|                                                        |   |   |    |    |   |             |    |   |              |   |   |   |   |   |   |   |   |   |   |   |   |
| Dr. Andrea Small-Howard, Chief Science Officer and Director | 2016   |   | $       | 63,000  |   |             | $       | -      |              |   |   |   |   |   | $ | - |   |   | $ | 63,000 |   |
|  2015                                                  |   | $      | 62,700  |    |   | $                | 756,000 |   |              |   |   |   |   | $ | 84,413 |   |   | $ | 903,113 |   |

----

----

| Name                |   | Number of shares underlying exercisable options/warrants                                                                                                           | Number of shares underlying unexercised options/warrants | Option exercise price ($)                                                                                                                                                                                                 | Option expiration date |                                                                                                                         | Number of shares that have not vested | Market value of shares that have not vested ($) |
|---------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|-------------------------------------------------|
| Craig Ellins        |   |                     5,000,000                                  | (2)                                                      |                                     - |                   |                    0.45       |                                  | 6/22/2018                                       |   |                               - |   |                            - |   |
| Andrea Small-Howard |   |                         200,000            | (3)                                                      |                         300,000                                                                   | (4)                    |                     0.17 |                                  | 3/27/2025                                       |   |                  300,000 | (6) |                  60,000 | (1) |
| John Poss           |   |                           20,000 | (3)                                                      |                         580,000                                                                   | (5)                    |                    0.30       |                                  | 8/10/2025                                       |   |                               - |   |   |   |

|  | · | each person who is known by us to be the beneficial holder of more than 5% of outstanding common stock; |
|--|--------|---------------------------------------------------------------------------------------------------------|

|  | · | each of named executive officers and directors; and |
|--|--------|-----------------------------------------------------|

|  | · | directors and executive officers as a group.  |
|--|--------|----------------------------------------------------|

----

| Name of Beneficial Owner (1)                  |   | Number of Shares of Common Stock Beneficialy Owned |       |   | Percentage of Shares Beneficially Owned |   |
|-----------------------------------------------|--------|----------------------------------------------------|------------|--------|-----------------------------------------|--------|
| Officers and Directors:                       |   |                                               |       |   |                                    |   |   |   |   |
| Craig Ellins                                  |   |                                               | 15,127,692 |   |                                    |   | (2 | ) |   |   | 26 | % |
| Dr. Andrea Small-Howard                       |   |                                               | 1,516,000  |   |                                    |   | (3 | ) |   |   | 3 | % |
| John Poss                                     |   |                                               | 586,667    |   |                                    |   | (4 | ) |   |   | 1 | % |
| Leslie Bosckor                                |   |                                               | 150,000    |   |                                    |   | (7 | ) |   |   | 0 | % |
| Shane Terry                                   |   |                                               | 150,000    |   |                                    |   | (7 | ) |   |   | 0 | % |
| Directors and officers as a group (5) persons |   |                                               | 17,530,359 |   |                                    |   |   |   |   |   | 30 | % |
| 5% Holders:                                   |   |                                               |       |   |                                    |   |   |   |   |   |   |   |
| Cesar Cordero-Kruger                          |   |                                               | 2,820,000  |   |                                    |   | (5 | ) |   |   | 5 | % |
| Lazarus Investment Partners, LLLP (6)         |   |                                               | 3,000,000  |   |                                    |   |   |   |   |   | 5 | % |

----

|                  |   | Fiscal 2016 |   |   | Fiscal 2015 |   |
|-----------------------|--------|-------------|--------|--------|-------------|--------|
| Audit Fees(1)         |   | $           | 17,050 |   |        | $      | 91,113 |   |
| Audit-Related Fees(2) |   |        | -      |   |        |   | - |   |
| Tax Fees(3)           |   |        | 6,950  |   |        |   | 3,035 |   |
| Subtotal              |   |        | 24,000 |   |        |   | 94,148 |   |
| All other Fees(4)     |   |        | 33,600 |   |        |   | - |   |
| Total                 |   | $           | 57,600 |   |        | $      | 94,148 |   |

|  | 1. | Growblox Sciences, Inc. Condensed Consolidated Financial Statements (including related notes to Condensed Consolidated Financial Statements) filed in Part II of this report are listed below: |
|--|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 2. | All schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission are not required under related instructions or are inapplicable and therefore have been omitted. |
|--|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|  | 3. | Exhibits |
|--|----|----------|

| No.        |   | Description                                                                                                                                                                                                                                      |
|------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1        |   | Articles of Incorporation (Incorporated by reference to an exhibit to Form SB-2 No. 333-82580 filed with the Commission on February 12, 2002)                                                                                                    |
| 3.2        |   | Amendment to Articles of Incorporation (Incorporated by reference to Exhibit 3.2 to Form S-1/A No. 333-82580 filed with the Commission on October 6, 2014 and Exhibit 3.2 to Form 10-K No. 333-82580 filed with the Commission on June 27, 2014) |
| 3.3        |   | Bylaws (Incorporated by reference to an exhibit to Form SB-2 No. 333-82580 filed with the Commission on February 12, 2002)                                                                                                                       |
| 10.1       |   | 2005 Restricted Stock Plan (Incorporated by reference to Annex A to Schedule 14A No. 333-82580 filed with the Commission on June 14, 2005)                                                                                                       |
| 10.2       |   | 2007 Restricted Stock Plan (Incorporated by reference to Exhibit 4.2 to Form S-8/POS No. 333-141467 filed with the Commission on February 8, 2008)                                                                                               |
| 10.3       |   | Amended Employment Agreement between Registrant and Craig Ellins dated June 19, 2014 (Incorporated by reference to Exhibit 10.3 to Form 10-K No. 333-82580 filed with the Commission on June 27, 2014)                                           |
| 10.4       |   | Amended Employment Agreement between Registrant and Craig Ellins dated June 22, 2015 (Incorporated by reference to Exhibit 10.3 to Form 10-K No. 000-55462 filed with the Commission on June 29, 2015)                                           |
| 10.5       |   | Amended Employment Agreement between Registrant and Andrea Small-Howard dated June 19, 2014 (Incorporated by reference to Exhibit 10.5 to Form 10-K No. 333-82580 filed with the Commission on June 27, 2014)                                    |
| 10.6       |   | Employment Agreement between Registrant and John Poss dated August 10, 2015 (Incorporated by reference to Exhibit 10.1 to Form 10-Q  No. 000-55462 filed with the Commission on November 18, 2015)                                          |
| 10.7       |   | Operating Agreement of GB Sciences Nevada LLC (Incorporated by reference to Exhibit 10.4 to Form S-1/A No. 333-82580 filed with the Commission on October 6, 2014)                                                                               |
| 10.8       |   | Asset Assignment, Acquisition and Professional Association Agreement with Craig Ellins (Incorporated by reference to Exhibit 10.1 to Form 8-K No. 333-82580 filed with the Commission on March 19, 2014)                                         |
| 10.9       |   | 2014 Equity Incentive Plan (Incorporated by reference to Exhibit 10.6 to Form S-1/A No. 333-198967 filed with the Commission on December 23, 2014)                                                                                               |
| 10.10      |   | Commercialization Agreement with Growblox Sciences Puerto Rico LLC (Incorporated by reference to Exhibit 10.1 to Form 8-K No. 333-82580 filed with the Commission on May 7, 2015)                                                                |
| 10.11      |   | Operating Agreement of Growblox Sciences Puerto Rico LLC (Incorporated by reference to Exhibit 10.2 to Form 8-K No. 333-82580 filed with the Commission on May 7, 2015)                                                                          |
| 10.12      |   | Note Purchase Agreement between Growblox Sciences, Inc. and Pacific Leaf Ventures LP (Incorporated by reference to Exhibit 10.1 to Form 8-K No. 333-82580 filed with the Commission on June 15, 2015)                                            |
| 10.13      |   | $1,750,000 6% senior secured convertible note issued to Pacific Leaf Ventures LP (Incorporated by reference to Exhibit 10.2 to Form 8-K No. 333-82580 filed with the Commission on June 15, 2015)                                                |
| 10.14      |   | Security Agreement between GB Sciences Nevada LLC and Pacific Leaf Ventures  LP (Incorporated by reference to Exhibit 10.3 to Form 8-K No. 333-82580 filed with the Commission on June 15, 2015)                                       |
| 10.15      |   | Royalty Agreement between Growblox Sciences, Inc. and Pacific Leaf Ventures LP (Incorporated by reference to Exhibit 10.4 to Form 8-K No. 333-82580 filed with the Commission on June 15, 2015)                                                  |
| 10.16      |   | Warrant to purchase 5,000,000 shares of common stock issued to Craig Ellins (Incorporated by reference to Exhibit 10.8 to Form 10-K No. 000-55462 filed with the Commission on June 29, 2015)                                                    |
| 10.17      |   | Employment Agreement between Registrant and Sandra Tiffany dated August 14, 2015 (Incorporated by reference to Exhibit 10.2 to Form 10-Q  No. 000-55462 filed with the Commission on November 18, 2015)                                     |
| 10.18      |   | Separation Agreement dated August 17, 2015 between GBS Sciences Nevada, LLC and GBS Nevada Partners, LLC (Incorporated by reference to Exhibit 10.3 to Form 10-Q  No. 000-55462 filed with the Commission on November 18, 2015)             |
| 10.19      |   | Medical Marijuana Establishment Management Agreement (Incorporated by reference to Exhibit 10.4 to Form 10-Q  No. 000-55462 filed with the Commission on November 18, 2015)                                                                 |
| 10.20      |   | Pacific Leaf Ventures LP Amended and Restated 6% Senior Secured Convertible Promissory Note (Incorporated by reference to Exhibit 10.1 to Form 8-K  No. 000-55462 filed with the Commission on February 12, 2016)                           |
| 10.21      |   | Pacific Leaf Ventures  LP Amended and Restated Royalty Agreement (Incorporated by reference to Exhibit 10.2 to Form 8-K  No. 000-55462 filed with the Commission on February 12, 2016)                                            |
| 10.22      |   | Pacific Leaf Ventures LP Omnibus Amendment and Waiver (Incorporated by reference to Exhibit 10.3 to Form 8-K  No. 000-55462 filed with the Commission on February 12, 2016)                                                                 |
| 10.23      |   | Amended Employment Agreement between Registrant and John Poss dated June 1, 2016                                                                                                                                                                 |
| 10.24      |   | Amended Employment Agreement between Registrant and Andrea Small-Howard dated June 1, 2016                                                                                                                                                       |
| 10.25      |   | Audit Committee Charter                                                                                                                                                                                                                          |
| 10.26      |   | Compensation Committee Charter                                                                                                                                                                                                                   |
| 14.1       |   | Code of Ethics (Incorporated by reference to Exhibit 14.1 to Form 10-KSB  No. 333-82580 filed with the Commission on June 22, 2004)                                                                                                         |
| 16.1       |   | Amended Letter from L J Sullivan & Co. C.P.A. to the Securities and Exchange Commission, dated July 22, 2015 (Incorporated by reference to Exhibit 16.1 to Form 8-K  No. 000-55462 filed with the Commission on July 22, 2015)          |
| 21.1       |   | List of Subsidiaries                                                                                                                                                                                                                             |
| 23.1  |   | Consent of Independent Public Accounting Firm                                                                                                                                                                                               |
| 31.1       |   | Certification of Chief Executive Officer pursuant to Rules 13a-14 and 15d-14 of the Securities Exchange Act of 1934                                                                                                                              |
| 31.2       |   | Certification of Chief Financial Officer pursuant to Rules 13a-14 and 15d-14 of the Securities Exchange Act of 1934                                                                                                                              |
| 32.1       |   | 18 U.S.C. Section 1350 Certification                                                                                                                                                                                                             |
| 101        |   | XBRL Instant Documents                                                                                                                                                                                                                           |

----

|   |  Growblox Sciences, Inc.  |
|--------|-------------------------------------|
|   |                                |   |
|   |                                |   |
|   | By:                                 | /S/  John Poss |
|   | Name:                               | John Poss |
|   | Title:                              | Chief Executive Officer, President and Chief Financial Officer |
|   |                                |     |

----